The Effect of Vorinostat on the Development of Resistance to Doxorubicin in Neuroblastoma
Published 2012 View Full Article
- Home
- Publications
- Publication Search
- Publication Details
Title
The Effect of Vorinostat on the Development of Resistance to Doxorubicin in Neuroblastoma
Authors
Keywords
Gene expression, Metabolic processes, Neuroblastoma, Protein domains, Gene ontologies, Gene regulation, Somatostatin, Neuroblastoma cells
Journal
PLoS One
Volume 7, Issue 7, Pages e40816
Publisher
Public Library of Science (PLoS)
Online
2012-07-20
DOI
10.1371/journal.pone.0040816
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- “Metabolic Reprogramming” in Ovarian Cancer Cells Resistant to Cisplatin
- (2011) M. Montopoli et al. CURRENT CANCER DRUG TARGETS
- Beyond reduction of atherosclerosis: PON2 provides apoptosis resistance and stabilizes tumor cells
- (2011) I Witte et al. Cell Death & Disease
- Outcomes for Children and Adolescents With Cancer: Challenges for the Twenty-First Century
- (2010) Malcolm A. Smith et al. JOURNAL OF CLINICAL ONCOLOGY
- Pediatric Phase I Trial and Pharmacokinetic Study of Vorinostat: A Children's Oncology Group Phase I Consortium Report
- (2010) Maryam Fouladi et al. JOURNAL OF CLINICAL ONCOLOGY
- Combination of Vorinostat and Flavopiridol Is Selectively Cytotoxic to Multidrug-Resistant Neuroblastoma Cell Lines with Mutant TP53
- (2010) J.-M. Huang et al. MOLECULAR CANCER THERAPEUTICS
- Trifluorothymidine Resistance Is Associated with Decreased Thymidine Kinase and Equilibrative Nucleoside Transporter Expression or Increased Secretory Phospholipase A2
- (2010) Olaf H. Temmink et al. MOLECULAR CANCER THERAPEUTICS
- Suppression of Hypoxia-Inducible Factor 2 Restores p53 Activity via Hdm2 and Reverses Chemoresistance of Renal Carcinoma Cells
- (2009) A. M. Roberts et al. CANCER RESEARCH
- Targeting Histone Deacetylases in Neuroblastoma
- (2009) O. Witt et al. CURRENT PHARMACEUTICAL DESIGN
- Long-Term Results for Children With High-Risk Neuroblastoma Treated on a Randomized Trial of Myeloablative Therapy Followed by 13-cis-Retinoic Acid: A Children's Oncology Group Study
- (2009) Katherine K. Matthay et al. JOURNAL OF CLINICAL ONCOLOGY
- Suberoylanilide hydroxamic acid (Zolinza/vorinostat) sensitizes TRAIL-resistant breast cancer cells orthotopically implanted in BALB/c nude mice
- (2009) S. Shankar et al. MOLECULAR CANCER THERAPEUTICS
- Initial testing (stage 1) of vorinostat (SAHA) by the pediatric preclinical testing program
- (2009) Nino Keshelava et al. PEDIATRIC BLOOD & CANCER
- Proteomic analysis of multidrug-resistance mechanisms in adriamycin-resistant variants of DLKP, a squamous lung cancer cell line
- (2009) Joanne Keenan et al. PROTEOMICS
- Regulation of Hypoxia-Inducible Factor 2 Signaling by the Stress-Responsive Deacetylase Sirtuin 1
- (2009) E. M. Dioum et al. SCIENCE
- lumi: a pipeline for processing Illumina microarray
- (2008) P. Du et al. BIOINFORMATICS
- Hypoxia-inducible factor-2: effect on radiation sensitivity and differential regulation by an mTOR inhibitor
- (2008) Rupal S. Bhatt et al. BJU INTERNATIONAL
- Histone deacetylase inhibitors enhance the chemosensitivity of tumor cells with cross-resistance to a wide range of DNA-damaging drugs
- (2008) Kei-ichi Ozaki et al. CANCER SCIENCE
- Histone Deacetylase 8 in Neuroblastoma Tumorigenesis
- (2008) I. Oehme et al. CLINICAL CANCER RESEARCH
Become a Peeref-certified reviewer
The Peeref Institute provides free reviewer training that teaches the core competencies of the academic peer review process.
Get StartedAsk a Question. Answer a Question.
Quickly pose questions to the entire community. Debate answers and get clarity on the most important issues facing researchers.
Get Started